

## Lixte Biotechnology Holdings Inc (LIXT) - Financial and Strategic SWOT Analysis Review

URL:	<a href="https://marketpublishers.com/r/LBD799AA218EN.html">https://marketpublishers.com/r/LBD799AA218EN.html</a>
Date:	July 12, 2017
Pages:	33
Price:	US\$ 125.00
ID:	LBD799AA218EN

Lixte Biotechnology Holdings Inc (LIXT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

### Highlights

Lixte Biotechnology Holdings Inc (Lixte) is a clinical stage pharmaceutical company, which focuses on the discovery of novel drugs for the treatment of cancer and non-malignant diseases. It develops comprises two classes of drugs, namely, protein phosphatase inhibitors (PTase-i) designated as the LB-100 series; and histone deacetylase inhibitors (HDACi), designated as the LB-200 series of compounds. The company's product pipeline comprises drug candidates for the treatment of cancer and neurodegenerative disorders such as solid tumors, acute ischemia and Gaucher's disease, among others. Its lead compound, LB-100 is being developed in Phase I clinical trials. Lixte established a cooperative research and development agreement with National Institute of Neurological Disorders and Stroke of the National Institutes of Health for development of its anti-cancer treatments. Lixte is headquartered in New York, the US.

### Lixte Biotechnology Holdings Inc Key Recent Developments

Jun 07,2016: Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Table of Content

### SECTION 1 - ABOUT THE COMPANY

Lixte Biotechnology Holdings Inc - Key Facts  
Lixte Biotechnology Holdings Inc - Key Employees  
Lixte Biotechnology Holdings Inc - Key Employee Biographies  
Lixte Biotechnology Holdings Inc - Major Products and Services  
Lixte Biotechnology Holdings Inc - History  
Lixte Biotechnology Holdings Inc - Company Statement  
Lixte Biotechnology Holdings Inc - Locations And Subsidiaries  
Head Office

### SECTION 2 – COMPANY ANALYSIS

Lixte Biotechnology Holdings Inc - Business Description

Lixte Biotechnology Holdings Inc - SWOT Analysis  
SWOT Analysis - Overview  
Lixte Biotechnology Holdings Inc - Strengths  
Lixte Biotechnology Holdings Inc - Weaknesses  
Lixte Biotechnology Holdings Inc - Opportunities  
Lixte Biotechnology Holdings Inc - Threats  
Lixte Biotechnology Holdings Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017  
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017  
Lixte Biotechnology Holdings Inc, Recent Deals Summary

### **SECTION 5 – COMPANY'S RECENT DEVELOPMENTS**

Jun 07, 2016: Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors

### **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions  
About GlobalData  
Contact Us  
Disclaimer

### **LIST OF TABLES**

Lixte Biotechnology Holdings Inc, Key Facts  
Lixte Biotechnology Holdings Inc, Key Employees  
Lixte Biotechnology Holdings Inc, Key Employee Biographies  
Lixte Biotechnology Holdings Inc, Major Products and Services  
Lixte Biotechnology Holdings Inc, History  
Lixte Biotechnology Holdings Inc, Key Competitors  
Lixte Biotechnology Holdings Inc, Ratios based on current share price  
Lixte Biotechnology Holdings Inc, Annual Ratios  
Lixte Biotechnology Holdings Inc, Annual Ratios (Cont.1)  
Lixte Biotechnology Holdings Inc, Interim Ratios  
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017  
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017  
Lixte Biotechnology Holdings Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios

Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## **LIST OF FIGURES**

Lixte Biotechnology Holdings Inc, Performance Chart (2012 - 2016)  
Lixte Biotechnology Holdings Inc, Ratio Charts  
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017  
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

## **COMPANIES MENTIONED**

Xenetic Biosciences Inc  
Array BioPharma Inc  
ArQule Inc

### I would like to order:

**Product name:** Lixte Biotechnology Holdings Inc (LIXT) - Financial and Strategic SWOT Analysis Review  
**Product link:** <https://marketpublishers.com/r/LBD799AA218EN.html>  
**Product ID:** LBD799AA218EN  
**Price:** US\$ 125.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/LBD799AA218EN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**